Particle number is one of the most common ways to express extracellular-vesicle dose. It is typically estimated using nanoparticle tracking analysis, tunable resistive-pulse sensing, or another particle-counting method. The apparent number depends on detection threshold, instrument settings, sample dilution, refractive properties, aggregation, and non-EV particles. Particle number therefore measures detectable particles rather than biologically active EVs. Two products administered at the same nominal particle dose can differ substantially in purity, size distribution, cargo, source, manufacturing process, and potency.
Figure 1 placeholder — Particle number
Protein quantity
Protein quantity expresses dose according to the total protein measured in an EV preparation, commonly as micrograms or milligrams. Protein assays are straightforward and historically common, but bulk protein includes EV membrane and cargo proteins together with co-isolated soluble proteins, protein aggregates, lipoproteins, and other contaminants. The relationship between total protein and particle number varies among preparations. Protein quantity is therefore a useful manufacturing or analytical measurement in some contexts but is not a universal surrogate for EV number, purity, or biological potency.
Figure 2 placeholder — Protein quantity
Cell-equivalent dose
Cell-equivalent dose relates an EV preparation to the number of producer cells, culture surface area, conditioned-medium volume, or another measure of cellular production. This can help describe upstream manufacturing yield, but it does not directly specify how many EVs were recovered or how biologically active they are. EV output changes with tissue source, donor, passage, confluence, culture duration, oxygen tension, stimulation, cell health, and collection strategy. Downstream recovery also varies. Cell-equivalent dose is therefore a process-linked metric rather than an interchangeable biological dose unit.
Figure 3 placeholder — Cell-equivalent dose
Cargo-based dosing
Cargo-based dosing attempts to define dose by the amount of a selected EV-associated molecule, such as a protein, lipid, messenger RNA, microRNA, or engineered therapeutic cargo. This approach can be mechanistically attractive when the cargo is known to mediate the intended effect. However, bulk cargo measurement does not establish vesicular localization, distribution among individual EVs, delivery efficiency, intracellular availability, or target engagement. A cargo-based dose becomes meaningful only when the selected molecule is analytically measurable, product-relevant, functionally linked to the mechanism, and quantitatively connected to biological activity.
Figure 4 placeholder — Cargo-based dosing
Functional assays
Functional assays measure a biological activity of the EV preparation rather than only a physical quantity. Examples may include modulation of inflammatory signaling, endothelial-cell responses, cell survival, receptor activation, gene-expression changes, or another mechanism-relevant effect. A potency assay intended for product control should be quantitative, reproducible, appropriately specific, and sufficiently sensitive to meaningful changes in product quality. Functional activity does not replace dose measurement; rather, it helps determine whether a stated amount of product has the expected biological activity.
Figure 5 placeholder — Functional assays
Dose-response testing
Dose-response testing evaluates whether changing the administered amount produces systematic changes in biological response. A credible relationship can help identify minimally active ranges, plateaus, saturation, loss of effect, or toxicity at higher exposures. EV dose-response studies must consider both concentration and exposure time, and in-vivo interpretation also depends on route, biodistribution, clearance, tissue exposure, and repeat dosing. A monotonic response should not be assumed: complex biological products can show threshold, bell-shaped, or context-dependent responses. Dose-response data should therefore be generated for the actual product and intended use.
Figure 6 placeholder — Dose-response testing
Lack of universal dosing standards
There is currently no universal dosing standard that makes particle number, protein mass, producer-cell equivalents, or cargo amount interchangeable across EV products. Differences in source cells, culture, separation, purity, composition, particle-counting methods, potency, route, indication, and recipient biology prevent simple conversion between products. Reporting a large particle number does not establish a high therapeutic dose, and a dose used in one study cannot automatically be transferred to another preparation. Clinically meaningful dosing standards will require product-specific analytical characterization, potency relationships, pharmacology, safety, and human dose-ranging evidence.
Figure 7 placeholder — Lack of universal dosing standards
Clinical takeaway
EV dose is not one universally defined quantity. Particle number, protein quantity, cell-equivalent dose, cargo amount, and functional potency describe different product attributes and cannot be assumed to be interchangeable.
Dose identity
A reported dose should specify exactly what was measured, the analytical method, units, sample preparation, and whether the value represents the final administered product. Ambiguous terms such as 'high dose' are not scientifically useful without a defined denominator.
Potency versus quantity
Quantity describes how much material is administered; potency describes biological activity associated with a defined amount. A large quantity of poorly active or contaminated material is not equivalent to a smaller quantity of a more active preparation.
Normalization
Research studies normalize EV exposure in different ways, including particles per cell, protein mass per cell, particles per body weight, or source-cell equivalents. The normalization method can materially affect comparisons and should be reported explicitly.
Route and exposure
Intravenous, local, intra-articular, inhaled, topical, and other routes produce different biodistribution and exposure. The same nominal dose can therefore create very different concentrations at the target tissue.
Repeat dosing
Repeated administration introduces additional variables including dosing interval, accumulation, clearance, immunologic responses, and changing recipient biology. Total cumulative dose does not fully describe temporal exposure.
Clinical interpretation
A marketed EV product should not be judged by particle count alone. A defensible dose claim connects product identity and purity to a validated measurement, functional potency, route, pharmacology, safety, and indication-specific human evidence.
Knowledge gaps
Major gaps include harmonized counting methods, validated potency assays, pharmacokinetic and biodistribution models, clinically relevant dose-response data, and methods for comparing lots without assuming that physical particle counts equal biological dose.
Bottom-line evidence statement
There is no universal EV dose unit. Strong dosing evidence defines what is being measured, demonstrates how that measurement relates to product potency and exposure, establishes dose-response and safety for the actual product, and avoids transferring nominal doses across non-equivalent preparations.
Additional controlled terminology
A nominal dose is the stated administered quantity, whereas biological dose refers to biologically meaningful exposure or activity. Potency can be assessed with a potency assay rather than inferred from total protein. A producer cell releases EVs into conditioned medium, but manufacturing yield does not define activity. Cargo localization, delivery efficiency, and target engagement determine whether a cargo-based amount becomes biologically meaningful. A dose-response relationship can identify a minimally active dose, plateau, or saturation and depends on exposure time, biodistribution, clearance, and repeat dosing. Normalization affects comparisons, while cumulative dose does not fully describe timing. A dose-ranging study is needed to connect an EV dose to safety and response.